文献速递姑息放疗与转移瘤放疗物理与技术

非脊柱骨寡转移SABR中临床靶区使用对结局的影响

Impact of clinical target volume utilization on outcomes in patients with non-spine bone oligometastases treated with stereotactic ablative radiation therapy.
PubMed 文献 · Radiother Oncol · 2025-05-21

该研究纳入加拿大不列颠哥伦比亚省SABR-5试验及BC寡转移登记中接受立体定向消融放疗的非脊柱骨转移患者,比较使用与不使用CTV的局部失败、边缘失败和毒性。结果显示CTV使用与局部失败、边缘失败及≥2级毒性均无显著差异,骨外侵犯和未接受系统治疗与局部-边缘失败风险升高相关。

要点

  • CTV使用与否的2年局部失败、边缘失败及≥2级毒性均无显著差异。
  • 骨外侵犯与局部-边缘失败风险升高相关(HR 2.59)。
  • 未接受系统治疗与局部-边缘失败风险升高相关(HR 0.27)。

核心结论

  • 在非脊柱骨寡转移SABR中,使用CTV与局部失败、边缘失败及毒性均无显著关联。
  • 骨外侵犯和未接受系统治疗与局部-边缘失败风险升高相关。

研究设计与样本

  • 共148例患者、183处非脊柱骨转移灶,按治疗计划是否使用CTV分层。

主要发现

  • 145处(79%)非脊柱骨转移灶治疗时使用了CTV。
  • 多数病灶接受35 Gy/5次(80%)或24 Gy/2次(15%)。
  • 使用CTV者2年局部失败8.6%(95%CI 3.9-13.2),未使用者8.1%(95%CI 0-16.8),p=0.53。
  • 边缘失败分别为6.4%(95%CI 2.3-10.5)和2.6%(95%CI 0-7.7),p=0.23。
  • 2年≥2级毒性累积发生率分别为15.8%(95%CI 9.7-21.9)和16.2%(95%CI 4.2-28.2),p=1.00。

关键数值与推荐

  • 多变量回归中CTV使用与局部-边缘失败风险无显著关联(HR 1.81,95%CI 0.62-5.31,p=0.28)。
  • 骨外侵犯与局部-边缘失败风险升高相关(HR 2.59,95%CI 1.2-5.7,p=0.02)。
  • 未接受系统治疗与局部-边缘失败风险升高相关(HR 0.27,95%CI 0.1-0.5,p=0.0002)。

临床怎么用

  • 对于非脊柱骨寡转移SABR,CTV使用与否不影响局部控制、边缘失败及毒性,可按临床实际选择。
  • 骨外侵犯或未接受系统治疗的患者局部-边缘失败风险较高,应加强随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare local failure, marginal failure, and toxicity in non-spine bone metastases (NSBMs) treated with versus without a CTV for stereotactic ablative radiotherapy (SABR). METHODS: The study included all patients in British Columbia treated with SABR for NSBMs on the SABR-5 trial (November 2016 - July 2020) and on the BC Oligometastases Registry (August 2020- October 2022). NSBMs were stratified based on CTV use for treatment planning. RESULTS: 148 patients with 183 NSBMs were included. 145 (79 %) NSBMs were treated with a CTV. Most lesions received 35 Gy in 5 fractions (80 %) or 24 Gy in 2 fractions (15 %). Local failure rates did not differ, with a 2-year local failure of 8.6 % (95 % confidence interval [CI] 3.9-13.2) with a CTV and 8.1 % (95 % CI 0-16.8) without a CTV (p = 0.53). Marginal failure did not differ (6.4 % [95 % CI 2.3-10.5] and 2.6 %, [95 % CI 0-7.7], respectively [p = 0.23]). 2-year cumulative incidence of grade ≥ 2 toxicity did not differ (15.8 %, 95 % CI 9.7-21.9 and 16.2 %, 95 % CI 4.2-28.2 respectively; p = 1.00). On multivariable regression, use of a CTV was not associated with the risk of local-marginal failure (hazard ratio [HR] 1.81, 95 % CI 0.62-5.31, p = 0.28). Extraosseous extension (HR 2.59, 95 % CI 1.2-5.7, p = 0.02) and lack of receipt of systemic therapy (HR 0.27, 95 % CI 0.1-0.5, p = 0.0002) were associated with higher risk. CONCLUSIONS: Use of a CTV was not associated with local or marginal failure or toxicity. Extraosseous extension and lack of receipt of systemic therapy were associated with higher risk of local-marginal failure.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. O'Reilly E, Johal E, Clark H, et al. Impact of clinical target volume utilization on outcomes in patients with non-spine bone oligometastases treated with stereotactic ablative radiation therapy. Radiother Oncol. 2025. PMID: 40409365. doi:10.1016/j.radonc.2025.110948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。